Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 454.25
(-3.03%)
USD 454.25
(-3.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.6 Billion USD | -9.52% |
| 2022 | 4.43 Billion USD | 55.81% |
| 2021 | 2.91 Billion USD | -12.52% |
| 2020 | 3.28 Billion USD | 118.68% |
| 2019 | 1.56 Billion USD | 119.83% |
| 2018 | 706.78 Million USD | 112.93% |
| 2017 | 103.25 Million USD | 1931.88% |
| 2016 | 75.46 Million USD | 103.24% |
| 2015 | -411.25 Million USD | 22.57% |
| 2014 | -598.75 Million USD | -221.1% |
| 2013 | -554.75 Million USD | 11983.19% |
| 2012 | 42.46 Million USD | -98.12% |
| 2011 | 133.93 Million USD | 133.48% |
| 2010 | -704.89 Million USD | -22.01% |
| 2009 | -598.87 Million USD | -18.77% |
| 2008 | -426.18 Million USD | -20.85% |
| 2007 | -385.21 Million USD | -87.27% |
| 2006 | -199.51 Million USD | -122.04% |
| 2005 | -114.44 Million USD | 12.48% |
| 2004 | -107.59 Million USD | -56.37% |
| 2003 | -264.52 Million USD | 29.4% |
| 2002 | -123.05 Million USD | -290.56% |
| 2001 | -97.13 Million USD | -64.36% |
| 2000 | -24.65 Million USD | 55.02% |
| 1999 | -44.3 Million USD | -16.85% |
| 1998 | -43.2 Million USD | -78.85% |
| 1997 | -15.6 Million USD | 7.69% |
| 1996 | -36.3 Million USD | 40.28% |
| 1995 | -22.8 Million USD | -36.06% |
| 1994 | -17.2 Million USD | -662.16% |
| 1993 | 5.1 Million USD | 140.22% |
| 1992 | -7.2 Million USD | -100.0% |
| 1991 | -3.8 Million USD | 7.32% |
| 1990 | -4.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 1.11 Billion USD | 138.61% |
| 2024 Q2 | -3.47 Billion USD | -347.75% |
| 2024 Q1 | 1.18 Billion USD | 10.34% |
| 2023 Q1 | 1.24 Billion USD | 12.16% |
| 2023 Q4 | 1.01 Billion USD | -18.12% |
| 2023 FY | - USD | -9.52% |
| 2023 Q2 | 1.28 Billion USD | 2.76% |
| 2023 Q3 | 1.24 Billion USD | -3.09% |
| 2022 Q4 | 1.11 Billion USD | -8.52% |
| 2022 Q1 | 962.2 Million USD | 8.85% |
| 2022 Q2 | 1.05 Billion USD | 9.3% |
| 2022 FY | - USD | 55.81% |
| 2022 Q3 | 1.21 Billion USD | 15.67% |
| 2021 Q1 | 832.73 Million USD | -8.03% |
| 2021 Q2 | -27.17 Million USD | -103.26% |
| 2021 Q4 | 884 Million USD | -19.58% |
| 2021 FY | - USD | -12.52% |
| 2021 Q3 | 1.09 Billion USD | 4144.58% |
| 2020 Q1 | 673.27 Million USD | -2.8% |
| 2020 FY | - USD | 118.68% |
| 2020 Q4 | 905.41 Million USD | 18.89% |
| 2020 Q3 | 761.52 Million USD | -10.18% |
| 2020 Q2 | 847.84 Million USD | 25.93% |
| 2019 FY | - USD | 119.83% |
| 2019 Q1 | 335.03 Million USD | 405.53% |
| 2019 Q4 | 692.69 Million USD | 685.61% |
| 2019 Q3 | 88.17 Million USD | -74.22% |
| 2019 Q2 | 341.97 Million USD | 2.07% |
| 2018 Q2 | 226.75 Million USD | 0.49% |
| 2018 Q4 | 66.27 Million USD | -54.13% |
| 2018 FY | - USD | 112.93% |
| 2018 Q1 | 225.66 Million USD | 79.99% |
| 2018 Q3 | 144.48 Million USD | -36.28% |
| 2017 Q3 | -147.91 Million USD | -375.49% |
| 2017 Q2 | 53.69 Million USD | -80.84% |
| 2017 Q1 | 280.29 Million USD | 584.17% |
| 2017 Q4 | 125.37 Million USD | 184.76% |
| 2017 FY | - USD | 1931.88% |
| 2016 Q2 | 2.47 Million USD | 126.83% |
| 2016 FY | - USD | 103.24% |
| 2016 Q1 | -9.23 Million USD | 83.41% |
| 2016 Q3 | -21.88 Million USD | -983.57% |
| 2016 Q4 | 40.96 Million USD | 287.19% |
| 2015 Q4 | -55.65 Million USD | 19.96% |
| 2015 Q1 | -180.37 Million USD | -17.69% |
| 2015 Q2 | -167.62 Million USD | 7.07% |
| 2015 FY | - USD | 22.57% |
| 2015 Q3 | -69.52 Million USD | 58.52% |
| 2014 Q3 | -105.35 Million USD | 26.52% |
| 2014 Q2 | -143.37 Million USD | 31.64% |
| 2014 Q4 | -153.25 Million USD | -45.47% |
| 2014 FY | - USD | -221.1% |
| 2014 Q1 | -209.74 Million USD | -174.29% |
| 2013 Q3 | -109.96 Million USD | -98.56% |
| 2013 Q2 | -55.38 Million USD | -114.29% |
| 2013 Q1 | 387.59 Million USD | 601.53% |
| 2013 Q4 | 282.35 Million USD | 356.77% |
| 2013 FY | - USD | 11983.19% |
| 2012 Q4 | -77.28 Million USD | -20508.53% |
| 2012 Q3 | -375 Thousand USD | 96.31% |
| 2012 Q2 | -10.17 Million USD | -111.06% |
| 2012 Q1 | 92 Million USD | -60.82% |
| 2012 FY | - USD | -98.12% |
| 2011 FY | - USD | 133.48% |
| 2011 Q1 | -152.78 Million USD | 22.49% |
| 2011 Q2 | -162.18 Million USD | -6.16% |
| 2011 Q3 | 321.08 Million USD | 297.97% |
| 2011 Q4 | 234.81 Million USD | -26.87% |
| 2010 Q4 | -197.12 Million USD | -2.7% |
| 2010 FY | - USD | -22.01% |
| 2010 Q1 | -157.23 Million USD | -39.97% |
| 2010 Q2 | -138.11 Million USD | 12.16% |
| 2010 Q3 | -191.94 Million USD | -38.97% |
| 2009 Q1 | -134.33 Million USD | -3.33% |
| 2009 Q4 | -112.33 Million USD | 22.72% |
| 2009 FY | - USD | -18.77% |
| 2009 Q2 | -140.82 Million USD | -4.83% |
| 2009 Q3 | -145.35 Million USD | -3.22% |
| 2008 FY | - USD | -20.85% |
| 2008 Q1 | -89.97 Million USD | -7.44% |
| 2008 Q3 | -120.9 Million USD | -49.31% |
| 2008 Q2 | -80.97 Million USD | 10.01% |
| 2008 Q4 | -130 Million USD | -7.53% |
| 2007 Q2 | -116.95 Million USD | -61.99% |
| 2007 Q1 | -72.19 Million USD | -185.64% |
| 2007 FY | - USD | -87.27% |
| 2007 Q3 | -105.19 Million USD | 10.06% |
| 2007 Q4 | -83.74 Million USD | 20.39% |
| 2006 FY | - USD | -122.04% |
| 2006 Q4 | -25.27 Million USD | 57.96% |
| 2006 Q3 | -60.12 Million USD | 15.94% |
| 2006 Q2 | -71.52 Million USD | -59.05% |
| 2006 Q1 | -44.97 Million USD | -62.65% |
| 2005 Q4 | -27.64 Million USD | -791.05% |
| 2005 Q2 | -35.55 Million USD | -12.04% |
| 2005 Q3 | 4 Million USD | 111.25% |
| 2005 FY | - USD | 12.48% |
| 2005 Q1 | -31.73 Million USD | -26.83% |
| 2004 Q3 | -24.26 Million USD | 22.41% |
| 2004 Q2 | -31.27 Million USD | -20.68% |
| 2004 Q1 | -25.91 Million USD | 35.49% |
| 2004 FY | - USD | -56.37% |
| 2004 Q4 | -25.01 Million USD | -3.1% |
| 2003 Q2 | -81.54 Million USD | -113.32% |
| 2003 Q4 | -102.25 Million USD | -2116.72% |
| 2003 Q3 | -85.25 Million USD | 102.44% |
| 2003 Q1 | 19.2 Million USD | -45.05% |
| 2003 FY | - USD | 29.4% |
| 2002 Q1 | -20.78 Million USD | -504.27% |
| 2002 FY | - USD | -290.56% |
| 2002 Q3 | -29.27 Million USD | -65.0% |
| 2002 Q4 | -26.36 Million USD | 9.99% |
| 2002 Q2 | -17.74 Million USD | 14.61% |
| 2001 Q2 | -14.38 Million USD | -11.79% |
| 2001 Q3 | -13.74 Million USD | 116.53% |
| 2001 Q1 | -12.87 Million USD | -11.47% |
| 2001 Q4 | -7.43 Million USD | -244.56% |
| 2001 FY | - USD | -64.36% |
| 2000 Q2 | 11.56 Million USD | 169.6% |
| 2000 FY | - USD | 55.02% |
| 2000 Q4 | -11.7 Million USD | -697.1% |
| 2000 Q3 | -12.85 Million USD | -83.27% |
| 2000 Q1 | -15.94 Million USD | -495.36% |
| 1999 Q2 | -11.7 Million USD | 60.99% |
| 1999 Q1 | -19.2 Million USD | -104.59% |
| 1999 FY | - USD | -16.85% |
| 1999 Q3 | -14.6 Million USD | -39.08% |
| 1999 Q4 | 4.1 Million USD | 134.71% |
| 1998 Q4 | -10.9 Million USD | -990.0% |
| 1998 FY | - USD | -78.85% |
| 1998 Q1 | -11.4 Million USD | -180.0% |
| 1998 Q2 | -8.5 Million USD | 44.81% |
| 1998 Q3 | -1 Million USD | 88.24% |
| 1997 Q1 | -4.8 Million USD | 27.27% |
| 1997 Q2 | -400 Thousand USD | 91.67% |
| 1997 Q4 | -5.5 Million USD | -17.02% |
| 1997 Q3 | -4.7 Million USD | -1075.0% |
| 1997 FY | - USD | 7.69% |
| 1996 Q2 | -7.4 Million USD | 172.53% |
| 1996 Q4 | -4.8 Million USD | 15.38% |
| 1996 FY | - USD | 40.28% |
| 1996 Q3 | -6.6 Million USD | -218.18% |
| 1996 Q1 | -7.8 Million USD | -213.79% |
| 1995 Q1 | -4.9 Million USD | 16.22% |
| 1995 FY | - USD | -36.06% |
| 1995 Q3 | -7 Million USD | 25.45% |
| 1995 Q4 | -1.3 Million USD | 64.63% |
| 1995 Q2 | -9.6 Million USD | -77.42% |
| 1994 FY | - USD | -662.16% |
| 1994 Q1 | -2.3 Million USD | -124.73% |
| 1994 Q2 | -4.5 Million USD | -95.65% |
| 1994 Q4 | -7.4 Million USD | -146.67% |
| 1994 Q3 | -3 Million USD | 33.33% |
| 1993 FY | - USD | 140.22% |
| 1993 Q1 | -2.7 Million USD | -15.38% |
| 1993 Q2 | 100 Thousand USD | 90.0% |
| 1993 Q4 | 9.7 Million USD | 504.35% |
| 1993 Q3 | -2 Million USD | -666.67% |
| 1992 Q2 | -1.5 Million USD | 4.76% |
| 1992 Q1 | -1.5 Million USD | -31.25% |
| 1992 FY | - USD | -100.0% |
| 1992 Q3 | -1.9 Million USD | -20.0% |
| 1992 Q4 | -2.2 Million USD | -8.33% |
| 1991 Q1 | 800 Thousand USD | 113.79% |
| 1991 Q4 | -1.2 Million USD | -23.08% |
| 1991 FY | - USD | -12.2% |
| 1991 Q3 | -1 Million USD | -44.44% |
| 1991 Q2 | -800 Thousand USD | -212.5% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 Q2 | 600 Thousand USD | 20.0% |
| 1990 Q4 | -5.8 Million USD | -1066.67% |
| 1990 Q3 | 600 Thousand USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 2923.25% |
| Dynavax Technologies Corporation | 9.66 Million USD | -47543.286% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -4586.654% |
| Perrigo Company plc | 646.2 Million USD | -612.659% |
| Illumina, Inc. | -608 Million USD | 857.434% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 57.359% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 1125.627% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 140.833% |
| IQVIA Holdings Inc. | 3.25 Billion USD | -41.437% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 4536.951% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 1.053% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 12452.01% |
| Waters Corporation | 1.02 Billion USD | -350.496% |
| Biogen Inc. | 2.37 Billion USD | -93.74% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 5367.48% |
| Evolus, Inc. | -41.81 Million USD | 11114.59% |
| Adicet Bio, Inc. | -136.53 Million USD | 3472.908% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 4014.322% |
| bluebird bio, Inc. | -167.16 Million USD | 2854.949% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 3167.924% |
| FibroGen, Inc. | -261.4 Million USD | 1861.711% |
| Agilent Technologies, Inc. | 1.67 Billion USD | -174.609% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 10463.506% |
| Homology Medicines, Inc. | -47.75 Million USD | 9743.186% |
| Geron Corporation | -174.78 Million USD | 2734.825% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 2118.753% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 5101.358% |
| Myriad Genetics, Inc. | -67.8 Million USD | 6892.33% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4667.427% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 1009.552% |
| Zoetis Inc. | 3.68 Billion USD | -24.972% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 9206.225% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | -295.62% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -1384.189% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 12863.151% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 2102.174% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 1831.298% |
| Verastem, Inc. | -83.16 Million USD | 5637.359% |
| Nektar Therapeutics | -243.1 Million USD | 1994.31% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 2146.837% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 5334.074% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 1148.552% |
| OPKO Health, Inc. | -65.51 Million USD | 7129.123% |
| Exelixis, Inc. | 196.6 Million USD | -2242.397% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -1006.753% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -4151.32% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 8359.56% |
| uniQure N.V. | -253.1 Million USD | 1919.518% |
| Imunon, Inc. | -20.78 Million USD | 22259.268% |
| Blueprint Medicines Corporation | -474.61 Million USD | 1070.308% |
| Insmed Incorporated | -654.73 Million USD | 803.364% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -918.969% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 1433.044% |
| TG Therapeutics, Inc. | 26.1 Million USD | -17544.444% |
| Incyte Corporation | 919.42 Million USD | -400.878% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 1011.379% |